Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

The Effect of HLA-B27 on Susceptibility and Severity of COVID-19

James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop and Dongseok Choi
The Journal of Rheumatology October 2020, jrheum.200939; DOI: https://doi.org/10.3899/jrheum.200939
James T. Rosenbaum
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James T. Rosenbaum
Hedley Hamilton
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Weisman
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael H. Weisman
John D. Reveille
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Winthrop
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin L. Winthrop
Dongseok Choi
Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dongseok Choi
  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Although many genes have polymorphisms, major histocompatibility complex genes are the most polymorphic. Many assume that the diversity of HLA increases the likelihood that a species can survive pandemics. Indeed, evidence suggests that HLA-B27 is protective for HIV1, hepatitis C2, and possibly influenza3.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Oct 2020, jrheum.200939; DOI: 10.3899/jrheum.200939

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Oct 2020, jrheum.200939; DOI: 10.3899/jrheum.200939
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Kiltz, et al reply
  • Hyperviscosity Syndrome in Rheumatoid Arthritis
  • Drs. Cron and Chatham reply
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire